The emergence of drug resistant mutants of HIV-1 is largely credited to its error 20 prone HIV-1 RT, making it important to studying its fidelity and bias. Previous HIV-1 21 RT studies rely on reporter genes (LacZ) as its template, leaving a gap of 22 understanding to how drug resistance mutations arise on HIV genes. This research 23 aims to characterize HIV-1 RT mutations on the Gag, protease, and RT p66 subunit 24 in an in-vitro selection pressure free assay for studying the emergence of drug 25 resistance mutations. Our results showed that known drug resistance mutations 26 occurred early with a general avoidance of key sites and detrimental mutations in the 27 backdrop of mutations rates of 4.71 x 10 -5 , 6.03 x 10 -5 , and 7.09 x 10 -5 mutations/bp 28 for Gag, protease and RT p66 respectively, with significant 'A to G' hypermutations 29 likely influenced by cellular adenosine deaminases. Silently mutating RT p66 to 30 study the effect of sequence on mutation rate and type, we observed an increase in 31 both rate (1.89 x 10 -4 mutations/bp) and 'A to G' hypermutations. Our study 32 demonstrates the importance of studying mutation emergence in HIV genes to 33 understand how fast drug resistance can emerge, and in this, provide potential 34 horizontal understanding to other viruses to understand how new viral disease and 35 drug resistance can emerge. 36
Introduction 37
Emerging viral infections are likely to be RNA viruses which are shown to 38 have a higher likelihood of undergoing genetic changes, leading to species jump 1 39 and efficient spread among humans 2 . Among the RNA viruses, the simian 40 immunodeficiency virus (SIV) lineages are believed to have ancestral links to the 41 human immunodeficiency virus, HIV-1 and HIV-2 3,4 . 42
HIV-1 Gag and protease play vital roles in viral assembly and maturation for 43 the production of infectious virions 5 . HIV-1 protease cleaves HIV-1 Gag and pol 44 polyproteins into functional subunits 6 . To prevent maturation, protease inhibitors (PI) 45 bind competitively against Gag to the active site of HIV-1 protease, thereby inhibiting 46 viral maturation 7,8 . To overcome PIs, drug resistance mutations on viral protease 47 reduce affinity to PIs 8,9 , and the accumulation of such resistance mutations 10-12 48 induced by HIV-1 RT 13,14 can render PIs ineffective and confer cross-resistance, 49 limiting drug selection 8 . In addition, mutations have been reported on HIV-1 Gag to 50 compensate for reduced viral fitness 8, 9, 14, 15 , with paired-mutations that work 51 synergistically in both HIV-1 Gag and protease also reported [16] [17] [18] [19] [20] . 52
The key to the generation of mutations in HIV genes is by the error prone HIV-53 1 reverse transcriptase (RT), an asymmetric heterodimer consisting of the p66 and 54 p51 subunits 21 . The p66 subunit performs the key enzymatic functions, catalysing 55 DNA polymerisation and cleaving the RNA of the RNA/DNA duplex 22,23 , while the 56 p51 subunit plays a supportive role to p66 24 . 57
Since most of the previous studies on HIV mutation rate were based on 58 reporter genes (LacZ) and not HIV genes, there is a gap in the understanding of HIV 59 RT mutation rates on HIV genes and when drug resistance mutations are 60 generated 25 . To fill this gap, we developed an in-vitro cell-based assay without 61 translational, immune and drug selection pressures to characterize the basal HIV-1 62 RT mutations and biases on HIV-1 Gag, protease, RT p66 genes, and a sequence 63 variant of RT p66 that had all codons silently mutated to investigate the effect of 64 codon usage on mutation rate. This in vitro assay allowed us to establish the native 65 error rate of HIV-1 RT to establish the rate, position and bias in HIV-1 Gag, protease, 66 RT p66 in the emergence of drug resistance. 67
Results 68
Characterization of HIV-1 Gag mutant variants 69
In our study, we classified 'A to G' mutations as hypermutations when multiple 70 mutations were found on the same sequence variant given that mutations are 71 expected to be consistently spread out. 72
We generated a total of 801 HIV-1 Gag sequences and found a mutation rate 73 of 3.36 x 10 -5 mutations/bp when excluding 'A to G' hypermutations and a slightly 74 higher rate of 4.71 x 10 -5 mutations/bp when including them, assuming the 75 experiment setup successfully mimicked one replication cycle (see Table 1 ). 76
There were more transitions (n = 24 excluding 'A to G' hypermutations, n = 40 77 when including 'A to G' hypermutations) as compared to transversions (n = 12) as 78 shown in Figure 1A . For nucleotide substitutions, 'A to G' substitutions were found to 79 be the highest (n = 20, 37.7%) when including 'A to G' hypermutations. When 80 excluding 'A to G' hypermutations, 'T to C' substitutions were the highest (n = 9, 81 25.0%), followed by 'G to A' and 'G to T' (n = 6, 16.7%), 'C to A' and 'C to T' (n = 5, 82 13.9%), 'A to G' (n = 4, 11.1%), and 'T to G' (n = 1, 2.8%), with several substitutions 83 not observed (see Figure 1B and 1C). 84 Analysis at the amino acid level showed missense mutations (n = 30, 55.6%) 85 to occur at approximately 2.0 times the frequency of silent mutations (n = 15, 27.8%, 86 see Figure 2 ) while nonsense mutations (n = 5, 9.3%) and frameshift mutations (n = 87 4, 7.5%) had lower occurrences. 88
Characterization of HIV-1 protease mutant variants 89
For HIV-1 protease, we generated a total of 640 sequences, finding a 90 mutation rate of 6.03 x 10 -5 mutations/bp (see Table 1 ), noting that no 'A to G' 91 hypermutations were found for protease. 92
As with Gag, there were more transition mutations (n = 6) than transversions 93 (n = 2) as shown in Figure 1A . 'G to A' substitutions were found to be the highest (n 94 = 3, 37.5%), followed by 'A to G' (n = 2, 25%), 'A to C', 'T to C' and 'C to A' (n = 1, 95 12.5%), with several substitutions not observed (see Figure 1B and 1C). 96
At the amino acid level, missense mutations (n = 4, 36.4%) occurred at 97 approximately 1.3 times the frequency of silent mutations (n = 3, 27.3%) and 98 frameshift mutations (n = 3, 27.3%), whereas nonsense mutations (n = 1, 9.1%) 99
were of lower occurrences (see Figure 2 ). 100
Characterization of HIV-1 RT p66 mutant variants 101
From 571 HIV-1 RT p66 subunit sequences, we calculated a mutation rate of 102 4.27 x 10 -5 mutations/bp when excluding 'A to G' hypermutations and 7.09 x 10 -5 103 mutations/bp when including them (see Table 1 ). 104
As with Gag and protease, there were more transition mutations (n = 18 105 excluding 'A to G' hypermutations, 45 including 'A to G' hypermutations) as 106 compared to transversions (n = 11) as shown in Figure 1A . 'A to G' substitutions 107 were found to be the highest (n = 29, 51.8%) only when including 'A to G' 108 hypermutations. When 'A to G' hypermutations were excluded, 'T to C' and 'G to T' 109 substitutions were instead the highest occurrences (n = 8, 27.6%), followed by 'G to 110 A' (n = 6, 20.7%), 'C to A' (n = 4, 12.5%), and 'A to G' and 'C to T' (n = 2, 6.9%). 111 There were several substitutions not observed (see Figure 1B and 1C). 112
Analysis after translation found relative consistency with Gag and protease 113
where missense mutations (n = 33, 49.3%) occurred at 1.7 times the frequency of 114 silent mutations (n = 20, 29.9%) as shown in Figure 2 . Nonsense mutations (n = 2, 115 3.0%) and frameshift mutations (n = 12, 17.9%) were of lower occurrences. 116
Characterization of HIV-1 Codon Mutated RT p66 mutant variants 117
A total of 700 codon mutated p66 gave a calculated mutation rate of 6.63 x 118 10 -5 mutations/bp when excluding 'A to G' hypermutations and 1.89 x 10 -4 119 mutations/bp when including them (see Table 1 ). 120 Consistent with the earlier mentioned genes, there were more transition 121 mutations (n = 38 excluding 'A to G' hypermutations, 177 including 'A to G' 122 hypermutations) as compared to transversion (n = 29) as shown in Figure 1A . As 123 with the wild-type p66, 'A to G' substitutions were found to be the highest (n = 139, 124 70.9%) only when including 'A to G' hypermutations. Excluding 'A to G' 125 hypermutations, 'G to T' substitutions were found to be the highest (n = 17, 25.4%), 126 followed by 'G to A' (n = 14, 20.9%), 'T to C' (n = 13, 19.4%), 'A to G' (n = 7, 10.4%), 127 'C to A' (n = 8, 11.9%), 'C to T' (n = 4, 6.0%), 'A to T' (n = 2, 3.0%), and 'T to A' and 128 'T to G' substitutions (n = 1, 1.5%), with the absence of the following substitutions: 'A 129 to C', 'C to G' and 'G to C' (see Figure 1B and 1C). For the codon mutated RT p66, two variants (20 and 80 a,b) containing deletions 152 without frameshifts are not shown. Silent, missense (conservative), missense (non-153 conservative), nonsense, frameshift (insertion) and frameshift (deletion) mutations 154 are shown in green, yellow, orange, grey, purple and pink, respectively. 155 Error rates were calculated as the ratio of the total number of mutations and the total number of 157 nucleotide bases, comparable to the reported range of 1.8 x 10 -5 -6.67 x 10 -4 , previously 158 reviewed 25,26 .
159

Mutation Rates of the Domains of HIV-1 Gag, protease, RT and RT p66 160
The HIV-1 genes were sorted into their respective domains and the mutation 161 rates calculated (see Figure 3 ). Within Gag, the overall mutation rates throughout the 162 domains were within a fairly narrow range of 2.29 to 4.46 x 10 -5 mutations/bp when 163 excluding 'A to G' hypermutations, and increasing to 8.16 x 10 -5 when including 164 them. 'A to G' hypermutations were found in the capsid (CA), nucleocapsid (NC), 165 and p6 subunits, but not the matrix (MA), p2 and p1 domains. Discussion 199
We set out to study the mutation rate of HIV-1 RT on HIV-1 Gag, protease 200 and RT p66 subunit in a single replication cycle using our in vitro BSL2 assay devoid 201 of selection pressures to establish the native mutation rate of HIV-RT on HIV genes. 202
Given the absence of translational, immune, fitness, and drug selection pressures in 203 our system, the observed biases are presumed to be intrinsic to HIV-RT and due to 204 host cell factors. Although mutations can be contributed from plasmid hosts (DH5α 205 and/or HEK293F), Q5 polymerase and sequencing artefacts, these were unlikely 206
given that the observed phenotypic mutations/bp/replication for E. coli and 207 mammalian cells were estimated to be 5.4×10 -10 and 5.0×10 -11 respectively 27 , and 208 that Q5 polymerase is among the most accurate commercial high-fidelity 209 polymerase 28 . Admittedly, there may be a role for primer selection bias when priming 210 the first few bases of the genes, and as such, these bases were excluded from 211 analysis and calculation of mutation rates. 212
Although numerous in vitro studies have attempted to establish the error rate 213 of HIV-1 RT (as previously reviewed 25,26 ), merely two utilised HIV-1 genes as their 214 template 29,30 . In our assay, we found the mutation rates of HIV-1 Gag, protease, RT 215 p66 and codon mutated p66 to be 4.71 x 10 -5 , 6.03 x 10 -5 , 7.09 x 10 -5 and 1.89 x 10 -4 216 mutations/bp (inclusive of hypermutations), respectively, within the range of 1.8 x 10 -217 5 -6.67 x 10 -4 mutations/bp previously reported 25, 26 . Across the HIV-1 genes, we 218 observed a predominance of transition mutations that is consistent with the 219 characterization across most phyla, previously hypothesized to conserve protein 220 functions 31-33 . Comparing the types of amino acid introduced, we observed a general 221 trend with missense mutations having the highest frequency, followed by silent 222 mutations, frameshifts and nonsense. This is notable because even in the absence 223 of selection pressures to maintain protein translatability, frameshift and nonsense 224 mutations (with more detrimental effects) were occurring at a lower frequencies, 225 possibly constrained by in-built genetic code probabilities 34 . 226
When changing the HIV-1 gene templates, a change in mutation rates, type of 227 mutations and mutational biases was also observed. In general, there were no A -T 228 or C -G mutations in the HIV genes studied, which were only detected in the codon 229 mutated p66 (see Figure 1 ), suggesting influence of the sequence or codon usage. 230
Comparing the HIV-1 codon mutated RT p66 to wild-type HIV-1 RT p66, the 231 mutation rate (1.89 x 10 -4 mutations/bp) increased by 2.7 folds as compared to 7.09 232
x 10 -5 . Interestingly, the RNase H domain of the codon mutated HIV-1 RT p66 was 233 also found to have a 7.1 folds increase (3.38 x 10 -4 mutations/bp), as compared to 234 the wild-type (4.79 x 10 -5 mutations/bp) suggesting RNA secondary structural 235 protection/susceptibility to host adenosine deaminases [35] [36] [37] . 236 Of the genes, the 'A to G' hypermutations were observed in HIV-1 Gag, RT 237 p66 and codon mutated RT p66, but not in protease, possibly due to its short 238 nucleotide length. In this, there is an interesting possibility that smaller genes 239 avoided the effects of A to G mutational effects that are likely caused by host 240 adenosine deaminases such as double-stranded RNA-specific adenosine 241 deaminase (ADAR) that deaminates 'A' residues to inosine (I) residues (read as 'G' 242 by ribosomes due to structural homology), leading to 'C' misincorporations in the 243 plus strand DNA after reverse transcription, and thus resulting in 'G' residues being 244 incorporated during second (minus) stand synthesis 38, 39 . As such, ADAR has been 245 shown to display both pro-viral and anti-viral activity 40-43 .. Given the lack of apparent 246 ADAR effects on protease, protease is likely the better target than HIV-1 RT or Gag, 247 which may explain the lower occurrences of PI resistance in clinical studies 44 , 248 alongside better potency than reverse transcriptase inhibitors (RTIs) 45 . 249
With 'A to G' hypermutations, there would be a general accumulation towards 250 G residues mutations for HIV-1 Gag, RT p66 and codon mutated RT p66, with the 251 exception of protease. Such 'G' biasness would result in increased glycine, arginine, 252 valine and alanine occurrence by the probability of codons 34 . On the contrary, this 253 probability will result in reduced phenylalanine, isoleucine, tyrosine, histidine and 254 asparagine presence in these genes. For HIV-1 protease, the mutational bias is 255 towards 'A' and 'C', which is also the case when 'A to G' hypermutations are not 256 Gag, suggesting that cleavage compensation mutations coud have emerged early in 269 the infection process even in the absence of drug seletion. Despite being of a single 270 replication cycle, our assay also detected known clinical drug resistance mutations 271 (see Supplementary Table 5 for the classified ones on Gag, protease, and p66). For 272 instance, in HIV-1 Gag, the observed E17K mutation (in the matrix) was previously 273 reported as a rare transient mutation implicated in cytotoxic T lymphocyte (CTL) 274 immune evasion resistance 46,47 . In HIV-1 protease, the observed K70T, previously 275 reported to be a minority mutation associated with resistance to PIs 48 was also found 276 in our assay. In HIV-1 RT p66, a known polymorphic mutation K103R (in the palm 277 domain) was observed, which when in combination with V179D (not found in our 278 assay), reduced susceptibility to non-nucleoside reverse transcriptase inhibitors 279 (NNRTIs): nevirapine (NVP) and efavirenz (EFV) by about 15 folds 49 . Interestingly, 280 the observed K103R originated from an 'A to G' mutation, specifically from "AAA" to 281 "AGA", suggesting that drug resistance mutations can be induced by host cell ADAR. 282
Few mutations were also found in crucial functional sites within the genes. In 283
HIV-1 Gag, we found P222L in the cyclophilin A (CyPA) binding site (along with 284 G221) that might potentially affect binding of the capsid to CyPA as previously 285 reported for P222A 50 . Given that the probability of P (CCT) to L (CTT) is 0.33 in 286 having a T substitution in the 2 nd codon position, and that P (CCT) to A (GCT) is also 287 0.33 in having the first C mutated to a G, there should be equal probabilities. 288
However, when considering that our Gag mutation analysis did not shown a 289 transition mutation link between C to G (shown in Figure 1 ), it is likely that the clinical 290 mutation is a rare-occurrence (under additional selection pressures like drug) or a 291 two or more mutation steps. Mutations A431D in the nucleocapsid and P453T in the 292 p6 domain were also observed, with reported clinical drug resistance counterparts as 293 A431V and a L449F/P453T pair 51 . In HIV-1 RT p66, the substitution F61S was 294 observed, in which the F61 residue was previously reported to play a vital role in 295 strand synthesis, with reported corresponding counterparts F61Y/L/W altering 296 activity 52 . Similarly, we observed P95L, in which P95 was reported to be at the 297 dimerization interface for the formation of the bottom of NNRTI pocket 53 , and 298 previously proposed to be a target amino acid in NNRTI design together with N137 299 and P140 54 . Interestingly, although P95 was reported to be in a highly conserved 300 location 53 , it was observed in our assay. 301
The occurrence of previously reported in vitro and clinical mutations in our 302 assay suggest that these mutations occurred without immune surveillance and drug 303 selection pressure (such as ART), occurring by probability within HIV gene specific 304 biases of RT (Figure 1) . The observation of a general avoidance of inducing 305 mutations at key regions/sites even at the nucleotide stage, seems to suggest in-built 306 barriers to detrimental mutations. Most relevant to the clinic is that these mutations 307 occurred within our mimic of a single cycle of replication. Considering that HIV-1 308 generates approximately 10 9 virions per day in an infected individual 55 which is 309 magnitudes higher than our hundreds of sequence variants per gene, clearly drug 310 resistance isolate can occur even within the first day of infection. 311
In the absence of selection pressures, mutations that are selected against can 312 be better detected, allowing for a more comprehensive analysis of the HIV-1 RT 313 bias. Using current methods, including the high-throughput ones like next-generation 314 sequencing, low frequency mutations can be missed to only emerge during intense 315 selection. Given that many HIV proteins can function in intense drug/immune 316 selection environments even with significant reduced activity 56,57 , an all-out 317 campaign against HIV could involve inhibitors against low-frequency occurring drug 318 resistance mutations. This pushes the HIV infection towards clearance by Muller's 319 ratchet 58-60 or by increasing viral mutation rate beyond pass a critical threshold 320 towards lethal mutagenesis, leading to the loss in genetic information and viability, 321 error catastrophe 61,62 . Since HIV-1 replicates at the edge of this critical threshold 63 , a 322 slight increase in the mutation rate may be sufficient to bring about error catastrophe, 323 which have been successfully induced previously by mutagenic nucleoside 324 analogues 64-66 . 325 Coupling with in silico tools, such as those incorporating probability mutational 326 change, it may be possible to identify mutational hotspots. As it was previously 327
shown that protease and RT drug cross resistance have a structural basis governed 328 by drug resistance mutations 67,68 , the bias of restricting specific amino acid changes 329 by the absence of A-T, C-G mutation occurrences can be exploited to constrain the 330 emergence of drug resistance. However, such an approach will require an in-depth 331 understanding of HIV-RT mutations that do not proceed to a protein level under the 332 most basic biological selection pressures of protein function. 333
Through the understanding of the mutational biases and mutation rate of HIV-334 1 RT, it possible to calculate the mutational events leading to the speciation jump 335 from an early SIV to the current HIV, making it important for surveillance for 336 emerging viral threats 2 . Although species jump is unpredictable, RNA viruses are 337 most likely to species jump after undergoing genetic changes 1 . 338 In conclusion, we have established an assay to generate and characterise 339 novel HIV-1 RT mutations on HIV-1 Gag, protease and RT p66 in a safe BSL2 340 manner, allowing insights to the mutational bias and mutation rate of HIV in the 341 absence of biological selection pressures. In our analysis, we also characterized the 342 likely effect of host factors e.g. ADAR which increased the genetic diversity beyond 343 the already error-prone RT. In this genetic diversity, we showed that we were able to 344 and 85°C for 5 min. RT negative controls were prepared without the addition of HIV-368 1 RT p51 and p66 subunits. 369
Amplification of cDNA and TOPO cloning 370
High-fidelity Q5 Polymerase PCR (New England Biolabs) was used to amplify cDNA 371 templates using the following primers for the respective genes: HIV-1 Gag -forward 372 (5 '-TAT TAG GAA TTC ATG GGT GCG AGA GCG-3') and reverse (5' -CTG 373 GTA AAG CTT CTA GTG GTG GTG GTG -3'); for protease -forward (5' -GCG 374 GCC GAA TTC ATG CCT CAA ATC AC -3') and reverse (5' -TAT AAT AAG CTT 375 CTA GTG GTG GTG GTG -3'); for RT p66 -forward (5' -ATG GCC TTG ACC 376 TTT GCT TTA CTG -3') and reverse (5'-CTT GTC GTC ATC GTC TTT GTA GTC 377 -3'); for codon mutated p66 -forward (5'-GCG GTG ATG GAT GGA CCA AAA 378 GTA AA -3') and reverse (5'-CTG CGC CTA ATG ATG ATG ATG AT -3') as per 379 manufacturer's recommendations. PCR products were analysed by gel 380 electrophoresis using GelApp 74 and purified using Gel extraction and PCR 381 purification kits as previously described 75 . Purified Q5 Polymerase PCR products 382 were cloned using Zero Blunt TOPO PCR cloning kit (Invitrogen) as per 383 manufacturer's protocol and transformed into in-house competent DH5α cells as 384 previously described 70 . Transformed DH5α cells were plated and grown overnight at 385 37°C on LB agar plates supplemented with kanamycin (50 µg/ml). Transformants 386 were screened using GoTaq PCR (Promega) with universal M13F (-20) forward and 387 reverse primers prior to sequencing. 388
Sequence analysis 389
Sequence assembly and alignment of HIV-1 sequences were performed using 390 YAQAAT Webserver (yaqaat.apdskeg.com). DNA2App 76 was used to translate 391 nucleotide sequences to their corresponding amino acid sequences. Previously 392 characterised HIV-1 sequences were retrieved from the Los Alamos sequence 393 database 77 . Mutations were identified through multiple sequence alignments with the 394 transfected sequence. To rule out sequencing artefacts, sequence chromatograms 395 were analysed, and ambiguous peaks and mutated sequences were sent for re-396 sequencing. Mutation rates were calculated as mutations/bp where the total number 397 of mutations and the total number of nucleotide bases of the respective HIV-1 genes 398 were compared. 399
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